FROG vs PATH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
FROG presents a dichotomy between strong growth fundamentals and concerning internal sentiment. The company maintains a stable financial health profile with a Piotroski F-Score of 5/9 and a pristine balance sheet (Debt/Equity of 0.01), though it remains GAAP unprofitable with a -13.50% profit margin. While revenue growth is robust at 25.20% and earnings consistently beat estimates, the bearish insider signal (CEO/CFO selling) and a 0/100 technical trend offset the 'Strong Buy' analyst consensus. The stock is currently valued as a high-growth asset, trading at a premium P/S ratio of 10.13.
UiPath exhibits strong fundamental health with a Piotroski F-Score of 8/9 and a very low Debt/Equity ratio of 0.04, indicating a robust balance sheet. While the stock is fundamentally undervalued with a PEG ratio of 0.36 and a current price ($10.30) well below its intrinsic value ($15.34), it is plagued by severe bearish sentiment. This is evidenced by a 0/100 technical trend and significant insider selling by the CEO. The conflict between high-quality financial metrics and poor market execution warrants a neutral stance until a technical reversal occurs.
Compare Another Pair
Related Comparisons
FROG vs PATH: Head-to-Head Comparison
This page compares JFrog Ltd. (FROG) and UiPath, Inc. (PATH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.